Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TransMedics Group, Inc. (TMDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TransMedics is a medical technology company focused on organ transplant therapy, and its filings give detailed insight into how it reports financial performance, manages risks, and documents material events related to its Organ Care System (OCS) and National OCS Program (NOP).
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue from OCS products and NOP services, operating expenses, and discussions of risk factors such as dependence on the OCS platform, regulatory approvals, logistics capabilities, indebtedness, and healthcare policy changes. Form 8-K current reports capture material events, including quarterly financial results, aircraft acquisitions for the NOP fleet, and other significant corporate developments.
TransMedics’ filings also discuss the acquisition and use of fixed-wing aircraft for transporting donor organs, its collaboration and logistics strategy, and the regulatory environment for both its medical devices and aviation transportation services. Disclosures highlight the importance of maintaining FDA and other regulatory approvals for OCS products and licenses for aviation operations.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points from lengthy filings, helping users quickly identify information on topics such as revenue drivers, risk factors, and logistics investments. Real-time updates from EDGAR, along with easy access to insider transaction reports on Form 4 and proxy materials on executive and governance matters, make this page a focused resource for analyzing TMDX’s regulatory record and corporate reporting over time.
TransMedics Group’s President and CEO Waleed H. Hassanein, through the Waleed H. Hassanein Revocable Trust, reported open‑market purchases of the company’s common stock. On August 6, 2025, the trust bought 8,400 shares at a weighted average price of $118.68.
On August 7, 2025, the trust made additional open‑market purchases of 6,617 shares at a weighted average price of $116.08 and 1,858 shares at a weighted average price of $116.85. After these transactions, the trust indirectly held 486,234 shares, and Hassanein directly held 121,424 shares.
Form 4 summary: Reporting person Edward M. Basile (Director) filed a Form 4 for TransMedics Group, Inc. (TMDX) reporting transactions dated 08/04/2025.
Key reported items
- Non-derivative rows list 4,143 shares associated with a transaction code M and a quoted price of $0.70.
- A contemporaneous non-derivative row lists 4,143 shares with transaction code S and a price of $125.51.
- Post-transaction beneficial ownership figures shown: 7,009 shares and 2,866 shares (as reported).
- Derivative disclosure: a stock option with conversion/exercise price $0.70, underlying 4,143 common shares, exercisable 02/16/2026, and 4,142 derivative securities reported as beneficially owned following the transaction.
- Explanations state the option is fully vested and was adjusted on a 3.5-for-1 basis in connection with a pre-IPO conversion.
Filing: Signed by Attorney-in-Fact Gerardo Hernandez on 08/05/2025.